Histogenics Corp. (NASDAQ:HSGX) shares saw an uptick in trading volume on Tuesday . 491,560 shares traded hands during trading, an increase of 554% from the previous session’s volume of 75,111 shares.The stock last traded at $3.55 and had previously closed at $2.82.

A number of research firms have issued reports on HSGX. Canaccord Genuity reiterated a “buy” rating on shares of Histogenics Corp. in a research note on Thursday, May 12th. BTIG Research reiterated a “hold” rating on shares of Histogenics Corp. in a research note on Sunday, May 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $9.75.

The firm’s market cap is $41.14 million. The firm has a 50-day moving average price of $2.03 and a 200 day moving average price of $2.19.

Histogenics Corp. (NASDAQ:HSGX) last posted its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.01. During the same period in the prior year, the firm posted ($0.58) EPS. Analysts forecast that Histogenics Corp. will post ($2.09) earnings per share for the current fiscal year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.